Suchergebnisse - "Myeloma"

PubPharm (14)

1

Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma : a retrospective study

enthalten in: BMC cancer | 2020

von Kondo, M. | Hotta, Y. | Yamauchi, K. | +4

2

Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

enthalten in: BMC cancer | 2020

von Kondo, M. | Hotta, Y. | Yamauchi, K. | +4

3

Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

enthalten in: BMC cancer | 2020

von Kondo, M. | Hotta, Y. | Yamauchi, K. | +4

4

Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

in: BMC Cancer | 2020

von Masahiro Kondo | Yuji Hotta | Karen Yamauchi | +4

5

Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma

enthalten in: Journal of clinical oncology | January 17, 2018

von Siegel, D. | Dimopoulos, M. | Ludwig, H. | +7

6

Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation

enthalten in: European journal of nuclear medicine and molecular imaging | January 2017

von Sachpekidis, C. | Hillengaß, J. | Goldschmidt, H. | +4

7

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma : analyzing surrogates of tumour mass and biology

enthalten in: European radiology | 15 January 2016

von Mai, E. | Kloth, J. | Merz, M. | +9

8

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

enthalten in: The lancet / Oncology | 2016

von Dimopoulos, M. | Goldschmidt, H.

9

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment : therapeutic implications

enthalten in: British journal of haematology | 19 September 2011

von Podar, K. | Zimmerhackl, A. | Fulciniti, M. | +10

10

Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation

enthalten in: Clinical cancer research | May 2009

von Hillengaß, J. | Zechmann, C. | Bäuerle, T. | +10